What Is the Russell-Silver Syndrome Growth Chart?

A Russell-Silver syndrome growth chart is a set of condition-specific reference curves built from the measured heights, weights, and head circumferences of hundreds of children who have Russell-Silver syndrome (RSS). Because children with RSS grow on a trajectory that falls far below the standard pediatric growth charts used in most clinics, plotting their data on a general-population chart makes nearly every one of them look alarmingly off the curve, which tells the clinician very little. An RSS-specific chart, by contrast, shows where a given child falls relative to other children with the same condition, turning the chart into a genuinely useful tool for spotting unexpected slowdowns, gauging the effect of treatment, and counseling families about realistic expectations.

Why Standard Growth Charts Fall Short

Standard growth charts, like those published by the World Health Organization or the U.S. Centers for Disease Control and Prevention, are built from measurements of healthy, typically developing children. They work well for the vast majority of kids. But Russell-Silver syndrome causes growth restriction that begins before birth and continues through childhood. A child with RSS will almost always plot below the second or third percentile on a standard chart, and many will plot completely off the bottom of the grid. When every checkup puts the child in the same extreme zone, the chart cannot distinguish between a child whose RSS growth is proceeding normally for the condition and a child who has an additional problem, like poor nutrition or a thyroid issue, on top of RSS.

That limitation prompted researchers to collect longitudinal growth data from large groups of children with confirmed RSS and build reference curves from those data. A landmark study drawing on 386 patients described normative data on spontaneous growth in RSS, giving clinicians a way to counsel families and to judge whether growth-promoting therapies were actually working above and beyond the expected RSS trajectory.¹ Before those condition-specific curves existed, there was no reliable baseline against which to measure progress.

What the RSS-Specific Curves Actually Track

An RSS growth chart typically includes separate curves for height-for-age, weight-for-age, and head circumference-for-age, split by sex, just like a standard pediatric chart. The key difference is scale. The median height on an RSS chart sits well below the general-population median, and the range of percentiles is narrower. A child plotting at the 50th percentile on the RSS chart might be at the first percentile or below on a standard chart.

Head circumference gets special attention. One of the hallmark features of RSS is relative macrocephaly, meaning the head is large not in absolute terms but relative to the child’s body size. A child’s head circumference might be at or near the normal range on a standard chart while the rest of the body is far below it. RSS-specific criteria define relative macrocephaly as head circumference at least 1.5 standard deviations above birth weight or length.² This discrepancy is itself a diagnostic clue, but it also means that tracking head circumference on a standard chart could mask the proportional imbalance that clinicians need to monitor.

Growth Restriction Begins Before Birth

RSS growth charts reflect a pattern that starts in utero, and prenatal ultrasound data help explain why the postnatal curves look the way they do. Compared to other babies born small for gestational age for non-syndromic reasons (such as placental insufficiency), fetuses with RSS already show markedly lower estimated weights and shorter femur lengths by mid-pregnancy. At the 22-week ultrasound, RSS fetuses had a median estimated weight near the 0th percentile, while non-syndromic small-for-gestational-age fetuses were around the 13th percentile. Abdominal circumference and femur length told the same story.³ By birth, roughly three-quarters of RSS infants had birth lengths more than three standard deviations below the mean, compared to about 15 percent of the non-syndromic group.

This prenatal growth restriction sets the starting point on any postnatal growth chart. An RSS-specific chart bakes that low starting point into its percentiles, so clinicians are not alarmed by a newborn plotting where virtually all RSS newborns plot. Instead, they can focus on whether the child’s trajectory is staying within or drifting away from the expected RSS corridor.

Postnatal Growth and the Role of Feeding Difficulties

After birth, children with RSS do not catch up the way many small-for-gestational-age babies do. Most remain well below the general population’s second percentile in height at age two, and severe feeding difficulties in the first years of life compound the problem.² Low caloric intake, combined with the underlying growth restriction, can push a child even further below the RSS curve if nutritional support is not aggressive enough. Many families find that tube feeding or high-calorie supplements are needed during infancy and toddlerhood.

This is one of the practical reasons an RSS-specific chart matters. A child with RSS who is gaining weight along the 25th percentile of the RSS chart is doing well for the condition. A child who starts slipping from the 25th to the 5th percentile of that same chart is flagging a problem, possibly inadequate nutrition, a gastrointestinal issue, or another medical concern layered on top of the syndrome. Without the condition-specific reference, that distinction disappears into the noise of an already-extreme standard-chart reading.

How Genetic Subtype Affects the Growth Trajectory

RSS is not a single genetic entity. The two most common molecular causes are loss of methylation at the 11p15 region (often abbreviated 11p15 LOM) and maternal uniparental disomy of chromosome 7 (mUPD7). A significant minority of clinically diagnosed RSS patients have neither of these findings and are classified as idiopathic. The growth trajectory can differ depending on the subtype.

Children with the 11p15 abnormality tend to be more severely affected at birth and to start growth hormone treatment at a lower height. In one long-term study, the mean starting height was about 3.7 standard deviations below the population mean for the RSS group overall, compared to about 2.9 standard deviations below the mean for non-syndromic short children born small for gestational age.⁴ Among RSS subtypes, children with mUPD7 showed a trend toward greater height gain with growth hormone treatment than those with 11p15 abnormalities, though the difference did not reach statistical significance in that particular study.

These subtype differences matter for families reading an RSS growth chart. A chart derived from a mixed cohort gives a broad picture, but a child with the mUPD7 subtype may track somewhat differently from one with the 11p15 subtype. Clinicians increasingly factor molecular diagnosis into their growth expectations rather than treating RSS as a single uniform entity.

Growth Hormone Treatment and What the Chart Can Show

Growth hormone (GH) therapy is the main medical intervention aimed at improving adult height in RSS. Children treated with GH gain substantially more height than those who are not, although the final adult height still tends to fall below the general population’s normal range.

One study of molecularly confirmed RSS patients found that the GH-treated group gained a median of about 1.5 standard deviations in height over the course of treatment, compared to roughly half a standard deviation in the untreated group. Despite that difference, the two groups ended up at similar final heights, around two to three standard deviations below the population mean. The reason is that the treated group started shorter, so they had more ground to make up just to converge with the untreated group’s endpoint.⁵ A separate study reported that median height went from about negative 2.7 standard deviations at the start of GH treatment to about negative 1.3 at final height, a significant improvement. Weight and body mass index also improved during treatment.⁶

An RSS growth chart helps clinicians evaluate whether GH therapy is producing a response above and beyond the natural RSS growth trajectory. Without the condition-specific baseline, any upward shift could be misread as simple catch-up growth, or conversely, a good response might look inadequate because the child is still far below the general population’s curves.

One concern families often have is whether GH treatment could worsen body asymmetry, since limb-length differences are common in RSS. A study of prepubertal children with RSS and lower-limb asymmetry treated with GH for three years found that height increased significantly but the asymmetry did not change.⁷ The growth was proportional to both limbs, so the pre-existing difference stayed stable rather than widening.

Bone Age, Puberty, and the Late-Childhood Growth Window

Bone age is another dimension that RSS growth charts implicitly account for. Young children with RSS often have delayed bone age, meaning their skeleton looks younger than their chronological age on an X-ray. This can be misleading in a reassuring way: delayed bone age is sometimes interpreted as meaning there is more time left to grow. In RSS, though, bone age tends to catch up rapidly during middle childhood and can actually leap ahead of chronological age by age nine to eleven.⁸

Puberty also arrives earlier in RSS than in non-syndromic children born small for gestational age, and earlier puberty means an earlier closure of the growth plates. The mUPD7 subtype tends to enter puberty earlier still than the 11p15 subtype.⁸ For families, this has a concrete consequence: the window during which GH can add inches is shorter than it might appear from the delayed bone age alone. Some clinicians consider puberty-delaying medications alongside GH to extend the growth window, though this is a case-by-case decision.

The two strongest predictors of final height with GH treatment are the child’s height at the start of treatment and how much height was gained by the onset of puberty.⁶ Starting treatment early and achieving a good first-year response matter more than how long treatment continues into puberty. This is where the RSS chart comes in again: it allows clinicians to spot a poor early response quickly rather than waiting for the child to fall further behind.

How RSS Growth Compares to Non-Syndromic Small-for-Gestational-Age Growth

RSS is sometimes grouped with the broader category of children born small for gestational age, and GH treatment for both groups falls under the same regulatory approval in many countries. But the growth trajectories differ in ways that matter.

Data from a large international growth study found that children with RSS started GH treatment younger (median age around seven, versus about nine for the broader small-for-gestational-age group) and at a lower height (about negative 3.4 standard deviations versus negative 2.8). Their birth weights were also lower, around negative 3.1 standard deviations versus negative 2.6 for the non-syndromic group. Crucially, the target height based on parental heights was close to average for the RSS group (about negative 0.1 standard deviations), while it was already somewhat low for the non-syndromic group (about negative 1.4).⁹ That gap between the child’s actual height and the genetic potential implied by parental height is wider in RSS, which is part of why GH treatment is so important for this group.

Adult height outcomes also diverge. In the long-term comparison, RSS adults who received GH ended up at about negative 2.2 standard deviations, while non-syndromic short-SGA adults reached about negative 1.7.⁴ The total height gained in standard-deviation terms was similar between the two groups, but RSS children started lower and therefore ended lower. A general small-for-gestational-age growth chart would set expectations too high for an RSS child and could lead to premature conclusions about treatment failure.

Diagnosis and Why Growth Charting Plays a Role

Growth charting is not just a monitoring tool for children already diagnosed with RSS. It also plays a role in getting to the diagnosis in the first place. One widely used clinical scoring system awards points for six features: being born small for gestational age (birth length or weight at or below negative 2 standard deviations), postnatal growth retardation (height at or below negative 2 standard deviations), relative macrocephaly at birth, body asymmetry, feeding difficulties or very low body mass index in toddlers, and a protruding forehead between ages one and three.¹⁰ Two of the six criteria are directly growth-related, and a third (feeding difficulties and low BMI) is closely connected. Accurate growth charting, including tracking the head-to-body size discrepancy, is what allows clinicians to recognize the pattern early enough to pursue molecular testing.

Body Composition and Metabolic Health in Adulthood

RSS growth charts are designed for childhood, but the growth story does not end when adult height is reached. Adults with molecularly confirmed RSS tend to have a body composition that looks different from what you might expect. Despite being small overall, they carry a higher percentage of body fat than the general population. In one study, median fat percentage in adults with RSS was about 44 percent, compared to roughly 30 percent in a reference cohort. Lean mass percentage was correspondingly lower, around 52 percent versus 66 percent. Bone mineral density was also reduced.¹¹

The metabolic profile in adulthood raises real flags. In that same study, about half the adults with RSS had total cholesterol at or above a clinically concerning threshold, a quarter had elevated fasting blood glucose, roughly a fifth had elevated triglycerides, and a third had hypertension.¹¹ These findings are consistent with the broader pattern seen in adults who were born very small for gestational age: a mismatch between a body programmed for scarcity in utero and the caloric environment after birth can tilt the metabolism toward fat storage and insulin resistance over time.

This matters for families tracking growth during childhood because it changes the frame. Encouraging rapid weight gain to push a child higher on a chart may seem like the right move, but clinicians managing RSS increasingly weigh the metabolic implications of aggressive nutritional catch-up. The goal is steady, appropriate growth for the condition rather than maximum possible weight gain.

Life Beyond the Numbers

Growth charts track centimeters and kilograms, but the lived experience of RSS extends well beyond what any chart captures. A qualitative study of people living with RSS identified four recurring themes: appearance-related concerns that go beyond height, strategies for dealing with perceived and real social threats, reports from women of pain and disability and feeling physically older than their years, and feeling overlooked in romantic relationships.¹² Participants described a mismatch between what healthcare providers focused on and what actually affected their day-to-day well-being.

For families using an RSS growth chart, this research is a useful reminder that the chart is a medical instrument, not a life-outcome predictor. A child who is tracking nicely along the RSS 50th percentile may still face challenges around body image, social confidence, and chronic discomfort that no amount of charting will address. Conversely, a child whose growth numbers look worrying may thrive in every other domain. The chart is essential for medical management. It is one piece of a much larger picture.